AstraZeneca: plans cell therapy manufacturing and innovation hub in Shanghai

AstraZeneca has announced a $15 billion investment in China through 2030, with a significant focus on advancing cell therapy and radioconjugate capabilities, particularly in Shanghai. The company plans to establish a global strategic center in Shanghai that will integrate R&D, commercial operations, and manufacturing, expanding its existing presence in the city, which already hosts its Asia-Pacific headquarters, China headquarters, and a global R&D center. This initiative aligns with AstraZeneca's broader strategy to leverage China's scientific expertise in novel modalities, including cell therapies, where the company aims to become the first global biopharmaceutical leader with end-to-end capabilities in the country.

The investment spans the entire value chain, from drug discovery to clinical development and manufacturing, and includes upgrades to existing facilities in Wuxi, Taizhou, Qingdao, and Beijing, as well as new sites to be announced. AstraZeneca has also strengthened its partnerships with Chinese biotech firms, such as Gracell Biotechnologies (acquired in 2024 for $1.2 billion) and AbelZeta Pharma, CSPC Pharmaceutical Group, Harbour BioMed, and Jacobio Pharma. These collaborations are critical to accelerating innovation in areas like cell therapy, where China's large patient populations and regulatory flexibility enable rapid development.

The company's CEO, Pascal Soriot, emphasized that China's role in global innovation is expanding, with AstraZeneca's R&D centers in Beijing and Shanghai leading over 20 global clinical trials to date. The investment is expected to grow AstraZeneca's workforce in China beyond 20,000 employees and create additional jobs across the healthcare ecosystem. The initiative also supports China's "Healthy China 2030" agenda by improving access to innovative treatments and fostering cross-border collaboration with institutions in the UK and beyond.